Global IV Iron Drugs Market Report: 2014 Edition



Koncept Analytics

$ 800

In Stock

Iron is one of the most important nutritional requirements of the human body as it plays an important role in managing many vital biological processes. These biological processes encompass synthesis of heme which forms the basis of hemoglobin; the oxygen-carrying protein of the blood; the formation of myoglobin, energy metabolism, neurotransmitter production, the formation of collagen and immune system function apart from others. An individual suffering from iron deficiency can maintain the requisite level of iron mainly through two types of supplements: oral iron supplements and intravenous iron supplements (IV). Treatment with oral iron supplements is simple, inexpensive and a relatively effective way of treating iron deficiency conditions; however, in many iron deficient conditions, oral iron is a less than the ideal treatment.

Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, ameliorating economic conditions, increasing global healthcare expenditures, and rising medicines expenditures. Some of the noteworthy trends and developments of this industry encompass novel product development, bundled payment systems and increasing penetration of genecology sector. However, the growth of this industrial sector is being hindered by stringent regulatory structures and adverse affects associated with the use of IV iron products.

The report analyzes the global iron products industry along with an extensive coverage of global and the US IV iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Content

1. Iron in Human Body: An Overview
1.1 IV Iron Application Areas
1.1.1 IV Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.2 Iron Deficiency Metrics
1.3 IV Iron Therapies for Anemia Treatment

2. Market Analysis
2.1 Global Iron Products Market
Market Value
Market Segments
2.1.1 Global IV Iron Market
Market Value
2.2 The US IV Iron Market
Market Value
Non-Dialysis IV Iron Market

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Improved Quality of Treatment outside Dialysis
3.1.2 Increasing Global Healthcare Expenditure
3.1.3 Shift from Rural to Urban Regions
3.1.4 Accelerating Aging Population
3.1.5 Increase in Number of Dialysis Cases
3.1.6 Growing Number of People Suffering from Hypertension
3.1.7 Improving Economic Conditions
3.1.8 Increasing Life Expectancy Rate
3.1.9 Increasing Coverage of Health Insurances
3.1.10 Rising Medicines Expenditures
3.2 Trends & Developments
3.2.1 Novel Product Development
3.2.2 Bundled Payment System
3.2.3 Increasing Penetration in Gynecology Sector
3.3 Challenges
3.3.1 Strict Regulatory Structures
3.3.2 Associated Adverse Effects with IV Iron Products

4. Competitive Landscape
4.1 The US
4.1.1 The US Non- Dialysis IV Iron Market
4.2 Product Contention

5. Company Profiles
5.1 Galenica Pharmaceuticals
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
Expansion into New Areas of Pharma Segment
Focus on Broadening Partnerships
5.2 Actavis Inc.
5.2.1 Business Description
5.2.2 Financial Overview
5.2.3 Business Strategies
Focus on Strategic Acquisitions & Partnerships
Expansion of Generic Product Line
5.3 AMAG Pharmaceuticals
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
Portfolio Expansion
Ceaseless Research & Development

6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

Risk Factors for CKD
FDA Approved IV Iron Products
SFP Clinical Trials
IV Iron Products – Safety Profile
IV Iron Administration Comparison
Dependent & Independent Variables (2007-2013)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

Global Iron Products Market (2009-2013)
Global Iron Products Market Share – by Segments (2013)
Global Iron Products Value – by Segments (2013)
Global IV Iron Market (2009-2013)
The US IV Iron Market Size (2009-2013)
US Non-Dialysis IV Iron Market (2011-2013)
IV Iron – Avoidance of ESA Initiation in Pre Dialysis Patients
Global Health Care Expenditure Per Capita (2007-2012)
The US Healthcare Expenditure per Capita (2007-2012)
Global Urban Population (2007-2012)
The US Urban Population (2007-2012)
Global Aging Population (Over 65) as a Percentage of Total Population (2008-2012)
The US Aging Population (2008-2012)
Global Dialysis Patient Population
Dialysis Patient Population Share by Region (2012)
Worldwide Patients with End Stage Renal Disease (2005-2013)
Hypertension Prevalence in the US (2010-2015E)
Hypertension Prevalence in the Developed Europe (2010-2015E)
Global GDP (2007-2012)
World Gross National Income (2008-2012)
Global Life Expectancy Rate (2007-2012)
The US Life Expectancy Rate (2007-2013E)
Global Insurance Density (2004-2013)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Long and Short Term Concerns about IV Iron
IV Iron Market Share in the US (2013E)
Non-Dialysis IV Iron Market in the US – by Volume (Q114)
Galenica’s Revenue Share by Business Segments (2012)
Galenica’s Net Sales and Net Profit (2009-2013)
Actavis’ Revenue Share by Business Segment (2013)
Actavis’ Revenues and Net Income (2009-2013)
AMAG Pharmaceuticals’ Revenues (2009-2013)
Global IV Iron Market Forecast (2009-2018F)